Inclusion Criteria:  Histologic proof of primary cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma. According to the 2018 International Federation of Cervical Cancer Obstetrics and Gynecology (FIGO) staging standard, the patient was diagnosed with local tumor ≥4cm in stage IB3, IIA2, IIB-IVA by at least one expert with associate high degree or above in the department of gynecology and gynecology. Age≥18 & ≤70. ECOG score 0-2. WBC ≥4.0×109/L, hemoglobin ≥60g/L, platelet ≥100.0×109/L; Serum bilirubin ≤ upper limit of normal, ALT, AST, ALP ≤ upper limit of normal ×2.5; Urea nitrogen (BUN) ≤ upper limit of normal ×1.5, creatinine (Cr)≤ upper limit of normal ×1.5. Patients with prior malignancy are eligible if disease-free ≥ 5 years. Signed study-specific informed consent form prior to study entry.  Exclusion Criteria:  Line has anti-tumor treatment, including chemotherapy, radiotherapy, surgery). Stage Ia1- IB2 and IVB cervical cancer. Patients with uncontrolled serious medical or mental illnesses. Women in pregnancy or lactation. Psychological, family, social factors, such as lead to no informed consent. Into the group of the first five years in addition to the cervical cancer merger other patients with a history of malignant tumor.